These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases. Sipos F; Firneisz G; Műzes G World J Gastroenterol; 2016 Sep; 22(35):7938-50. PubMed ID: 27672289 [TBL] [Abstract][Full Text] [Related]
4. MYC activation is a hallmark of cancer initiation and maintenance. Gabay M; Li Y; Felsher DW Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890832 [TBL] [Abstract][Full Text] [Related]
12. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Schaub FX; Dhankani V; Berger AC; Trivedi M; Richardson AB; Shaw R; Zhao W; Zhang X; Ventura A; Liu Y; Ayer DE; Hurlin PJ; Cherniack AD; Eisenman RN; Bernard B; Grandori C; Cell Syst; 2018 Mar; 6(3):282-300.e2. PubMed ID: 29596783 [TBL] [Abstract][Full Text] [Related]
13. The MYC oncogene is a global regulator of the immune response. Casey SC; Baylot V; Felsher DW Blood; 2018 May; 131(18):2007-2015. PubMed ID: 29514782 [TBL] [Abstract][Full Text] [Related]
14. MYC Analysis in Cancer and Evolution. Hartl M; Bister K Methods Mol Biol; 2021; 2318():87-117. PubMed ID: 34019288 [TBL] [Abstract][Full Text] [Related]
15. MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages. Dhanasekaran R; Hansen AS; Park J; Lemaitre L; Lai I; Adeniji N; Kuruvilla S; Suresh A; Zhang J; Swamy V; Felsher DW Cancer Res; 2023 Feb; 83(4):626-640. PubMed ID: 36525476 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies to inhibit MYC. McKeown MR; Bradner JE Cold Spring Harb Perspect Med; 2014 Oct; 4(10):. PubMed ID: 25274755 [TBL] [Abstract][Full Text] [Related]
17. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis. Pelengaris S; Abouna S; Cheung L; Ifandi V; Zervou S; Khan M BMC Biol; 2004 Dec; 2():26. PubMed ID: 15613240 [TBL] [Abstract][Full Text] [Related]
18. The new role for an old guy: MYC as an immunoplayer. Marinkovic D; Marinkovic T J Cell Physiol; 2021 May; 236(5):3234-3243. PubMed ID: 33094851 [TBL] [Abstract][Full Text] [Related]
19. Noncanonical roles of the immune system in eliciting oncogene addiction. Casey SC; Bellovin DI; Felsher DW Curr Opin Immunol; 2013 Apr; 25(2):246-58. PubMed ID: 23571026 [TBL] [Abstract][Full Text] [Related]
20. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]